Investor Presentaiton
The figure shows
domestic firms which have
received more than
USD20M in financing from
a single VC company
(other investors not listed)
and their HQ locations.
These companies are
currently in different
growth stages.
More than half of the
companies are
headquartered in Yangtze
River Delta (YRD) cities,
especially Suzhou, one of
the key biomedical
markets in the country.
Some investment firms
with exposure to
biomedical firms are
exploring opportunities to
invest in the life sciences
real estate (LSRE) sector.
China Life Sciences
-
2022
Life science companies with HQs in China funded by a large VC company
Financing volumes in $, 1H/22
Correctseq
正序生物
HQ location
Brii Biosciences
65.9M, Beijing
新元素医药
Atam Bescance & l'harmaceutical
62.0M, Suzhou
EDGE VEDICAL
精锋医疗
183.7M, Shenzhen
ABclonal
170.2M, Wuhan
A 数坤科技
SHU KUN
158.4M, Beijing
123M, Beijing
InferVision
METIS
PHARMACEUTICALS
92.3M, Hangzhou
SyMap
VISION X
艾康特医疗科技
81.4M, Suzhou
77.6M, Zhuhai
SceneRay
43.7M, Suzhou
A
36.8M, Hangzhou
Pleco Specialty Pharmacology Services
安波生物
31.6M, Shanghai magAssist 55.9M, Suzhou
AMADOR BIOSCIENCE
Starting up
Clinical trial
Growth stages
Income
generating
Pharmalegacy 59.7M, Shanghai
Profiting
Source: Savills Research using PitchBook dataView entire presentation